NASDAQ: IMMPImmutep Ltd Stock
$0.38+0.00 (+0%)
Updated Jul 30, 2026
IMMP Price
$0.38
Fair Value Price
$0.01
Market Cap
$56.00M
52 Week Low
$0.29
52 Week High
$3.53
P/E
-0.94x
P/B
0.8x
P/S
57.67x
PEG
N/A
Dividend Yield
N/A
Revenue
$7.65M
Earnings
-$56.32M
Gross Margin
100%
Operating Margin
-777.3%
Profit Margin
-777.7%
Debt to Equity
0.49
Operating Cash Flow
-$42M
Beta
1.02
Next Earnings
Sep 4, 2026
Ex-Dividend
N/A
Next Dividend
N/A
IMMP Overview
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine IMMP's potential to beat the market
- IMMP doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
IMMP
RankedUnranked of 462
RankedUnranked of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $258.38 | A | |
| $11.06 | A | |
| $8.42 | A |
Be the first to know about important IMMP news, forecast changes, insider trades & much more!
IMMP News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how IMMP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
IMMP ($0.38) is overvalued by 2,737% relative to our estimate of its Fair Value price of $0.01 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
IMMP ($0.38) is not significantly undervalued (2,737%) relative to our estimate of its Fair Value price of $0.01 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
IMMP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more IMMP due diligence checks available for Premium users.
Valuation
IMMP fair value
Fair Value of IMMP stock based on Discounted Cash Flow (DCF)
Price
$0.38
Fair Value
$0.01
Overvalued by
2,737.00%
IMMP ($0.38) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
IMMP ($0.38) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
IMMP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
IMMP price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.94x
Industry
20.57x
Market
17.04x
IMMP price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.8x
Industry
5.4x
IMMP is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
IMMP's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
IMMP's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
IMMP's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$98.8M
Liabilities
$32.4M
Debt to equity
0.49
IMMP's short-term assets ($99.14M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IMMP's short-term assets ($99.14M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IMMP's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
IMMP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
IMMP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
IMMP vs Biotech Stocks
Immutep Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.